Intrabronchial activated protein C enhances lipopolysaccharide-induced pulmonary responses

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 188-197

  Kager, Liesbeth M ^a   De Boer, J Daan ^a   Bresser, Paul ^a,b   Van Der Zee, Jaring S ^a,b   Zeerleder, Sacha ^a,c   Meijers, Joost C M ^a   Van'T Veer, Cornelis ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CCL14A CHEMOKINE; CCL15 CHEMOKINE; CHEMOKINE; CXCL11 CHEMOKINE; CXCL7 CHEMOKINE; CXCL9 CHEMOKINE; DROTRECOGIN; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 2; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; LEUKOCYTE COUNT; LUNG LAVAGE; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL;

ADULT; BRONCHOALVEOLAR LAVAGE; BRONCHOSCOPY; HEMOSTASIS; HUMANS; INFLAMMATION; INTERVENTION STUDIES; LIPOPOLYSACCHARIDES; LUNG; MALE; PROTEIN C; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; TIME FACTORS; YOUNG ADULT;

EID: 84880165234     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00057112     Document Type: Article

References (37)

1. Levi M, Schultz MJ, Rijneveld AW, et al. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003; 31: S238-S242. (Pubitemid 36458173)
2. Wygrecka M, Jablonska E, Guenther A, et al. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost 2008; 99: 494-501. (Pubitemid 351549285)
3. Choi G, Schultz MJ, Levi M, et al. Protein C in pneumonia. Thorax 2005; 60: 705-706.
4. Hataji O, Taguchi O, Gabazza EC, et al. Activation of protein C pathway in the airways. Lung 2002; 180: 47-59. (Pubitemid 36002438)
5. Imokawa S, Sato A, Hayakawa H, et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156: 631-636. (Pubitemid 27352005)
6. Schouten M, Van De Pol MA, Levi M, et al. Early activation of coagulation after allergen challenge in patients with allergic asthma. J Thromb Haemost 2009; 7: 1592-1594.
7. Schultz MJ, Millo J, Levi M, et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-135. (Pubitemid 38223484)
8. Choi G, Schultz MJ, van Till JW, et al. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24: 786-789. (Pubitemid 39504432)
9. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285: L514-L521. (Pubitemid 37022850)
10. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-462. (Pubitemid 30129452)
11. Arndt PG, Young SK, Worthen GS. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway. J Immunol 2005; 175: 4049-4059. (Pubitemid 41292068)
12. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172. (Pubitemid 46572500)
13. Weiler H. Regulation of inflammation by the protein C system. Crit Care Med 2010; 38: Suppl. 2, S18-S25.
14. Hoogerwerf JJ, de Vos AF, Levi M, et al. Activation of coagulation and inhibition of fibrinolysis in the human lung on bronchial instillation of lipoteichoic acid and lipopolysaccharide. Crit Care Med 2009; 37: 619-625.
15. van der Poll T, Levi M, Nick JA, et al. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171: 1125-1128. (Pubitemid 40663724)
16. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxininduced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104: 3878-3885. (Pubitemid 39620133)
17. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709. (Pubitemid 32204987)
18. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global openlabel trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33: 2266-2277. (Pubitemid 41437481)
19. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-1341. (Pubitemid 41362701)
20. Marti-Carvajal AJ, Sola I, Lathyris D, et al. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011; 4: CD004388.
21. Hofstra JJ, Vlaar AP, Cornet AD, et al. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 2010; 23: 105-111.
22. Cornet AD, Hofstra JJ, Vlaar AP, et al. Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats. Shock 2011; 36: 417-423.
23. Slofstra SH, Groot AP, Maris NA, et al. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006; 149: 740-746. (Pubitemid 44748066)
24. Maniatis NA, Letsiou E, Orfanos SE, et al. Inhaled activated protein C protects mice from ventilator-induced lung injury. Crit Care 2010; 14: R70.
25. Hoogerwerf JJ, de Vos AF, Bresser P, et al. Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med 2008; 178: 34-41. (Pubitemid 351919191)
26. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-2100. (Pubitemid 26307911)
27. Schuepbach RA, Velez K, Riewald M. Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain. Blood 2011; 117: 6338-6346.
28. Suzuki K, Gabazza EC, Hayashi T, et al. Protective role of activated protein C in lung and airway remodeling. Crit Care Med 2004; 32: Suppl. 5, S262-S265.
29. Yuda H, Adachi Y, Taguchi O, et al. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood 2004; 103: 2196-2204. (Pubitemid 38326238)
30. Yasui H, Gabazza EC, Tamaki S, et al. Intratracheal administration of activated protein C inhibits bleomycininduced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001; 163: 1660-1668. (Pubitemid 32578773)
31. Shimizu S, Gabazza EC, Taguchi O, et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 2003; 167: 1416-1426. (Pubitemid 36609728)
32. Waerhaug K, Kuzkov VV, Kuklin VN, et al. Inhaled aerosolised recombinant human activated protein C ameliorates endotoxin-induced lung injury in anaesthetised sheep. Crit Care 2009; 13: R51.
33. Macias WL, Dhainaut JF, Yan SC, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72: 391-402. (Pubitemid 35178865)
34. Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115: 1121-1130.
35. Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest 2010; 120: 3167-3178.
36. Cao C, Gao Y, Li Y, et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010; 120: 1971-1980.
37. Elphick GF, Sarangi PP, Hyun YM, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009; 113: 4078-4085.